



Godavari Biorefineries Ltd

Dated: July 07, 2025

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street
Mumbai-400001

Script Symbol: GODAVARIB

Script Code:544279

Sub: Press Release

Dear Sir / Madam,

Pursuant to regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, please find enclosed press release titled “Godavari **Biorefineries’ European Patent for Anti-Cancer Molecule Now Validated in Key Jurisdictions**”

This is for your information and records.

Thanking you,
Yours faithfully

For Godavari Biorefineries Limited

Manoj Jan
Company Secretary & Compliance Officer
Membership No.F-7998

MANOJ
JAIN

Digitally signed by
MANOJ JAIN
Date: 2025.07.07
08:05:28 +05'30'



Godavari Biorefineries' European Patent for Anti-Cancer Molecule Now Validated in Key Jurisdictions

Anti cancer Patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states

Mumbai, July 07, 2025: Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB) announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. This milestone underscores the company's growing presence in high-impact scientific innovation, led by its dedicated Anti-Cancer Research Segment.

The patented molecule has demonstrated **efficacy against both cancer cells and cancer stem cells**, marking a promising advance toward more targeted and effective cancer therapies. It has shown **potential in the treatment of various cancers**, including **breast and prostate cancer**, with encouraging **efficacy and safety profiles in preclinical animal studies**. The molecule is currently in Phase 1a clinical trials to assess safety in human patients with advanced solid tumors as well as in healthy volunteers.

"This patent validation marks a significant milestone in our journey toward advancing original, high-quality scientific research," said **Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited**. "It reflects the dedication of our teams and our aspiration to contribute meaningfully to global knowledge and innovation."

Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its investment in translational research that addresses some of the world's most urgent health challenges.

This development highlights GBL's growing diversification into advanced scientific domains, complementing its leadership in ethanol, bio-based chemicals, and renewable materials produced from agricultural feedstocks.

About Godavari Biorefineries Limited (GBL):

Godavari Biorefineries Limited (BSE: Script Code 544279 | NSE: GODAVARIB) is a leader in the renewable chemicals and biofuels industry, dedicated to creating sustainable solutions that contribute to a circular economy. Listed on the BSE Limited (BSE) and the National Stock Exchange of India Limited (NSE), GBL has a legacy of innovation and a commitment to sustainability, driving progress in renewable energy and green chemistry. For more information about Godavari Biorefineries, please visit www.godavaribiorefineries.com.

Media Contact:

Pushpendra Dhansoia

Corporate Communications - GBL

Email: dhansoia.pushpendra@somaiya.com

Phone: +91 9029037173